Women's Health

Receiving the vaccine during pregnancy is cited as crucial for both confronting disproportionate infant vulnerability and easing the disease burden for new and expecting mothers.

Maternal outcomes and disparities may be improved through postpartum navigation, in which a mother works with their provider to navigate barriers to care.

Legal challenges have made dispensing abortion medications more difficult than ever.

Only 4% of money for research and development is used to focus on women’s health issues.

A substantial collection of evidence indicates that the fallopian tube serves as the primary site of origin for a large portion of high-grade serous ovarian cancers.

Results from a recent study indicated that lowering the threshold for abnormal blood pressure in the second half of pregnancy from 140/90 mm Hg would not increase accuracy in identifying maternal or perinatal risk in patients.

A recent study being presented at the American College of Cardiology Latin America 2023 conference found the prevalence of cardiotoxicity among patients with breast cancer undergoing chemotherapy was 11.94%.

Chronic pain is among the comorbidities for people diagnosed with HIV, but there has been a lack of data on the prevalence and risk factors in women.

Approximately 1 in 8 women in the United States experience postpartum depression.

Methamphetamine deaths among American Indian and Native Alaskan men and women significantly increased between 1992 and 2019.

The approval of norgestrel (Opill) is expected to help reduce barriers to access by allowing people to obtain the medication without needing to see a health care provider.

Vasomotor symptoms include hot flashes and night sweats, which can negatively impact a woman's quality of life.

Discussions around women’s health should extend beyond talking about menstruation and pregnancy to include all aspects of health.

Common treatments for acne are known to be unsafe for pregnant women, but alternative treatments exist that are safe for use; however, actual treatment patterns within this patient population are unclear.

A recent clinical trial showed positive results from the selective neurokinin-1,3 receptor antagonist elinzanetant (Bayer) against menopausal vasomotor symptoms.

According to a recent study, the association between employment status and contraceptive use observed in a period before the Affordable Care Act (ACA) was not found after the ACA ended.

According to a recent study, pregnant women infected with COVID-19 experienced significant maternal mortality during pregnancy, with worse outcomes during the second wave of the pandemic compared to the first.

This comes after a district court in Texas ruled to keep Mifepristone available, but with heavy restrictions.

Over 400 pharmaceutical employees and executives signed an open letter in a show of solidarity with the FDA, but some say that big pharma’s actions helped lead to this moment in the first place.

A recent study showed a link between menopause and increased glaucoma risk, with estrogen-based treatment being a possible solution.

The FDA, state governors, and OB/GYN groups around the country are fighting back against Judge Matthew Kacsmaryk’s ruling.

The risk of developing breast cancer was greater in women who are currently using or recently used progestogen-only contraceptives, a recent study showed.

The drug, called Lumisight, is an optical imaging agent that detects cancerous tissue during initial lumpectomy to allow for a more complete resection. An NDA has been submitted to the FDA.

There was a lower probability of initiating psycholeptics and experiencing postpartum psychiatric emergencies in study patients who continued using antidepressants

Drug Topics will continue to update this story as new information becomes available.

Results from a phase 3 study show that the drug is effective in treating VMS symptoms due to menopause.

The drug, called Makena, was intended to stop premature births, but has not been effective in its goal, says the FDA.

The expansion was based on 4-year data from the monarchE study.

Developing innovative solutions for women with depression, accounting for differences in gender and sex, are critically important

The drug, manufactured by Sandoz, will treat conditions including osteoporosis in postmenopausal women